logo
Plus   Neg
Share
Email

Aviva To Sell Its Entire 80% Shareholding In Aviva Vita S.p.A.

Aviva plc (AV.L,AV), on Monday, said it agreed to sell its entire 80% shareholding in the Italian life insurance joint venture, Aviva Vita S.p.A., to its partner UBI Banca.

Upon completion, Aviva would receive about €400 million in cash consideration. The company noted that the transaction would increase Aviva's net asset value as at June 30, 2020 by £0.12 billion, strengthen Aviva's Solvency II capital surplus by £0.22 billion and increase its Solvency II coverage ratio on a shareholder basis by about 4 percentage points. In 2019, Aviva Vita's IFRS profit after tax was £523 million and it did not pay a dividend. The gross assets of Aviva Vita were £16.32 billion as at June 30, 2020.

Aviva would use the proceed to further strengthen its central liquidity. Further, the proceed would be considered as part of Aviva's broader capital management and debt reduction objectives.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J&J Distributing has recalled various food products citing potential contamination with Listeria monocytogenes or Lm, an organism that can cause serious and sometimes fatal infections. According to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS, around 33 pounds of ready-to-eat meat and poultry salads and wrap products have been called back. The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate.
Follow RTT